In this regard, the current phase 1–2 trials of ADC antibody and CART targeting ROR2 for other tumor types (e.g., NSCLC and ovarian tumors: ClinicalTrials.gov #NCT03504488, NCT03960060, NCT03393936, [30]) may also benefit ALK+ ALCL patients. Here, ROR2 is linked to neoplasm.